BridgeBio Pharma Inc. [BBIO] Is Currently 5.76 below its 200 Period Moving Avg: What Does This Mean?

BridgeBio Pharma Inc. [NASDAQ: BBIO] jumped around 0.74 points on Thursday, while shares priced at $13.58 at the close of the session, up 5.76%. The company report on March 23, 2023 that BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb’s OPDIVO® (nivolumab).

– BBP-398, an investigational SHP2 inhibitor, is a potentially best-in-class therapy for use in combination approaches, which is shown by preclinical findings demonstrating its safety profile, continuous, once-daily dosing regimen and synergistic efficacy to treat cancers driven by KRAS mutations.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.


– If successful, the combination of investigational therapy BBP-398 and OPDIVO has the potential to address the serious unmet need for patients with KRAS-mutated non-small cell lung cancer (NSCLC) and other advanced solid tumors with KRAS mutations.

BridgeBio Pharma Inc. stock is now 78.22% up from its year-to-date (YTD) trading value. BBIO Stock saw the intraday high of $13.65 and lowest of $12.28 per share. The company’s 52-week high price is 19.94, which means current price is +91.27% above from all time high which was touched on 03/07/23.

Compared to the average trading volume of 2.70M shares, BBIO reached a trading volume of 3357877 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about BridgeBio Pharma Inc. [BBIO]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BBIO shares is $26.12 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BBIO stock is a recommendation set at 1.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Cowen have made an estimate for BridgeBio Pharma Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on February 06, 2023. While these analysts kept the previous recommendation, SVB Leerink dropped their target price from $66 to $24. The new note on the price target was released on December 27, 2021, representing the official price target for BridgeBio Pharma Inc. stock. Previously, the target price had yet another drop from $86 to $25, while Mizuho kept a Buy rating on BBIO stock.

The Average True Range (ATR) for BridgeBio Pharma Inc. is set at 1.24, with the Price to Sales ratio for BBIO stock in the period of the last 12 months amounting to 28.68.

How has BBIO stock performed recently?

BridgeBio Pharma Inc. [BBIO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.67. With this latest performance, BBIO shares gained by 11.04% in over the last four-week period, additionally plugging by 26.80% over the last 6 months – not to mention a rise of 23.01% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BBIO stock in for the last two-week period is set at 52.39, with the RSI for the last a single of trading hit 49.78, and the three-weeks RSI is set at 53.97 for BridgeBio Pharma Inc. [BBIO]. The present Moving Average for the last 50 days of trading for this stock 11.64, while it was recorded at 13.49 for the last single week of trading, and 10.15 for the last 200 days.

BridgeBio Pharma Inc. [BBIO]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and BridgeBio Pharma Inc. [BBIO] shares currently have an operating margin of -603.28 and a Gross Margin at +89.95. BridgeBio Pharma Inc.’s Net Margin is presently recorded at -619.70.

Return on Total Capital for BBIO is now -69.88, given the latest momentum, and Return on Invested Capital for the company is -73.05. Additionally, BBIO Total Debt to Total Capital is recorded at 367.54, with Total Debt to Total Assets ending up at 276.64.

Reflecting on the efficiency of the workforce at the company, BridgeBio Pharma Inc. [BBIO] managed to generate an average of -$1,215,109 per employee. Receivables Turnover for the company is 4.22 with a Total Asset Turnover recorded at a value of 0.09.BridgeBio Pharma Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.50 and a Current Ratio set at 4.50.

Insider trade positions for BridgeBio Pharma Inc. [BBIO]

There are presently around $1,966 million, or 98.10% of BBIO stock, in the hands of institutional investors. The top three institutional holders of BBIO stocks are: KOHLBERG KRAVIS ROBERTS & CO. L.P. with ownership of 31,060,971, which is approximately 0% of the company’s market cap and around 4.30% of the total institutional ownership; VIKING GLOBAL INVESTORS LP, holding 26,620,991 shares of the stock with an approximate value of $361.51 million in BBIO stocks shares; and VANGUARD GROUP INC, currently with $143.83 million in BBIO stock with ownership of nearly 5.869% of the company’s market capitalization.

Positions in BridgeBio Pharma Inc. stocks held by institutional investors increased at the end of Thursday and at the time of the Thursday reporting period, where 83 institutional holders increased their position in BridgeBio Pharma Inc. [NASDAQ:BBIO] by around 8,101,735 shares. Additionally, 98 investors decreased positions by around 8,820,020 shares, while 27 investors held positions by with 127,863,967 shares. The mentioned changes placed institutional holdings at 144,785,722 shares, according to the latest SEC report filing. BBIO stock had 25 new institutional investments in for a total of 883,014 shares, while 26 institutional investors sold positions of 3,702,756 shares during the same period.


Please enter your comment!
Please enter your name here